Can older adults lose weight on semaglutide — and is it safe?

Does semaglutide actually work for older adults, or do the trials not apply to them?

This is a reasonable concern. Early drug trials often skew younger, and it is fair to ask whether the headline figures translate. In the STEP 1 trial (published in the New England Journal of Medicine and central to Wegovy's UK approval) participants ranged broadly in age, and subgroup analyses did not show older adults being systematically excluded from benefit. Average weight loss across the trial was around 15% over 68 weeks at the 2.4 mg dose.

That said, older people were not the majority of STEP 1's cohort, so direct extrapolation has limits. What we can say with confidence is that NICE, when it recommended semaglutide (TA875), did not place an age ceiling on eligibility, the criteria centre on BMI, the presence of weight-related comorbidities, and whether treatment is delivered alongside appropriate support. Age itself is not a disqualifier.

One practical point worth knowing: if you are curious about how semaglutide works for weight loss in people without diabetes, slowing gastric emptying and reducing appetite signals does not become less relevant with age. If anything, cardiovascular risk reduction may carry extra weight (literally) for older patients. The SELECT trial data on semaglutide and major cardiovascular events is relevant context here; you can read more about semaglutide's cardiovascular outcomes on a dedicated page.

What specific risks are higher for older patients on semaglutide?

Honesty matters here. Older adults face a different risk landscape, and that shapes how a prescriber will think about this.

The most discussed concern is sarcopenia, the loss of muscle mass that naturally accelerates after 60. Semaglutide reduces overall body weight, but weight lost from calorie restriction and reduced appetite is not all fat. Without attention to protein intake and resistance exercise, some of that loss comes from lean tissue. This does not mean treatment should be avoided; it means it should be managed thoughtfully, ideally with dietary guidance alongside it.

Gastrointestinal side effects (nausea, vomiting, looser stools, slowed digestion) are the most commonly reported effects across all age groups. In older adults who may already have lower fluid reserves, prolonged vomiting or diarrhoea raises a higher risk of dehydration and, by extension, strain on kidney function. The NHS semaglutide medicines page sets out which symptoms need prompt attention.

Polypharmacy (taking several medicines simultaneously) is more common in older patients. Semaglutide slows gastric emptying, which can alter the absorption timing of other oral medicines. A prescriber must review the full medicines list. This is not a theoretical risk; it is a practical one that a thorough consultation addresses directly.

If you want a quick check before your consultation: write down every medicine you currently take, including over-the-counter tablets and supplements. That list, ready to share, saves time and helps your prescriber assess the picture properly.

Does having type 2 diabetes change things for an older person considering semaglutide for weight loss?

Many older adults asking about weight loss also live with type 2 diabetes, and the two questions are connected. Wegovy (semaglutide 2.4 mg) is licensed for weight management, while Ozempic (also semaglutide, but at different doses) is licensed for type 2 diabetes. These are distinct products with distinct licences; an older adult with diabetes who wants to use semaglutide for weight loss should discuss this carefully with their prescriber or GP, who will consider which product and indication is appropriate for their situation. There is a fuller explanation of how the two licences interact on a dedicated page.

For older people without diabetes, semaglutide for weight loss without diabetes follows the same BMI-based eligibility as for any adult, though the clinical review will naturally pay close attention to kidney function, blood pressure, and other age-related factors.

Who should an older person talk to, and what does the assessment involve?

The starting point is a prescriber who can review your full health picture. That means not just your BMI, but your current medicines, any existing conditions, kidney and liver function where relevant, and what you are hoping treatment will do. Semaglutide is a prescription-only medicine; no reputable service will approve it without that review. The NHS England guidance on weight management injections outlines what that clinical wrap-around support should look like.

On the NHS, Wegovy is available through specialist weight management services under NICE TA875, but waiting times can be long and criteria are strict. For older adults who do not meet the NHS thresholds or prefer not to wait, a private prescription from a regulated pharmacy is a legal route, provided clinical assessment takes place first. If you are weighing up whether the medicine is right for you, it is also worth reading about whether semaglutide affects the heart, particularly if you have an existing cardiovascular condition.

At nume, every consultation is reviewed personally by a GPhC-registered prescriber (a real clinician, not automated software) on the same day. If semaglutide is not clinically suitable for your situation, we will say so clearly. You can explore all available weight-loss treatments through a free consultation, or read more about how Wegovy works before you decide.

Pregnancy, breastfeeding, and trying to conceive: semaglutide is not recommended in any of these situations, regardless of age. The medicine's effects on a developing baby are not established, and UK clinical guidance is clear that treatment should be stopped before conception is attempted. Anyone in this situation should speak to their GP.